Clinical perspectives on MAVENCLAD® (cladribine 10mg tablets), for highly active relapsing multiple sclerosis (MS), and real-world experiences from members of the multidisciplinary MS team

Posted in Sponsored Feature on 1st Mar 2019

This MS-DIGEST paper summarises the key data from the MAVENCLAD® clinical development programme. In a separate commentary, clinical experts from the multidisciplinary MS team share their thoughts on the clinical data and provide insights into real-world experiences of introducing MAVENCLAD® into clinical practice.

Download this Article

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

See a sample email newsletter here
This website is for medical professionals only.